George Eleftheriou
CEO

Feel Therapeutics develops an AI-enabled Digital Precision Medicine Platform to objectively diagnose and manage mental health conditions. The platform continuously collects physiological and digital biomarker data from various sources to compute metrics related to mood, stress, and sleep. This objective data is then integrated into personalized Digital Therapeutic (DTx) and patient support programs for enhanced mental health outcomes.
Raised to date
$29MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Individuals often struggle to understand and manage their mental health due to a lack of objective, continuous data and personalized support. Traditional mental health care relies on infrequent, subjective assessments, making it difficult to track progress and provide timely interventions.
Feel Therapeutics offers an AI-powered digital precision medicine platform that provides continuous, passive monitoring of mental health. The platform uses data collected from wearables, digital health apps, and clinician dashboards to generate physiological and digital biomarkers related to mood, stress, sleep, psychomotor activity, and cognitive functioning. These biomarkers are then integrated into personalized digital therapeutic programs, offering real-time interventions and support at the point of need. By moving from point-of-care to point-of-need, Feel Therapeutics aims to provide objective understanding and accessible mental health support.
The primary target audience includes individuals seeking to improve their mental health and well-being, as well as healthcare and life science organizations looking for objective, data-driven solutions for mental health monitoring and treatment.